KG LEGAL \ INFO
BLOG

Electronic cross-border health services – MyHealth@EU

publication date: December 13, 2022

Aim

Undoubtedly, the need to exchange IT data has been increasing for several years. One of such areas is medicine, which has already become a relatively computerized field during the COVID 19 pandemic, e.g. obtaining a referral for vaccination in Poland consisted in issuing it in the Internet IT system, it could not be obtained in a traditional written form. This is a procedure that speeds up all medical procedures, which the European Union strives to achieve by creating and disseminating the MyHealth@EU program.

MyHealth@EU

MyHealth@EU is a program that accelerates the exchange of health informatics data and can be defined as the European Health Digital Service Infrastructure. The most important assumption is that E-prescriptions and patient cards will be available in all EU countries by the end of 2025.

Personal data as the basis for action

More

3D bionic pancreas – great potential to be used. A team of scientists from Poland is looking for investors

What is a 3D bionic pancreas?

publication date: December 13, 2022

It is a ready-made medical device made of living cells and biomaterials, i.e. biological elements, and printed using 3D technology. It will primarily apply to patients with type 1 diabetes who experience severe complications. This is a huge breakthrough and an original idea of Polish scientists led by Dr. Michał Wszoła. This is an opportunity for patients as effective as transplantation, and at the same time less invasive compared to pancreatic islet transplantation. As a result, it will require neither a deceased donor nor immunosuppressive treatment.

An alternative to a transplant

More

European Medicines Regulatory Network adopts EU common standard electronic product information

publication date: November 29, 2022

Dissemination of impartial and up-to-date information on all medicines available to patients in the EU through electronic channels

The European medical market currently offers many substances with various medicinal properties, coming from many sources, often purchased from foreign distributors. Medicines are imported by the Member States of the European Union depending on the demand. Due to the multitude and variety of substances available on the medical market, in order to ensure consumer safety, it is necessary to provide access to comprehensive information on the substance admitted to the market, its properties, effects and possible side effects. Both the persons responsible for dispensing the medicine and the consumers purchasing them should have such knowledge.

The European Medicines Regulatory Network has adopted a common standard for electronic product information (ePI) on medicines in the European Union, the initiative aims to provide better and wider access to the database containing data on a specific medicinal substance. The information made available via electronic channels is primarily to be reliable, up-to-date and available to all interested parties. The establishment of common EPI standards in the European Union will streamline the process of providing and updating information provided to patients, consumers and healthcare professionals, thanks to which decisions regarding the consumption of a given substance will be more informed.

More

Virtual power plants in Poland

A solution to an eternal problem

One might venture to say that no matter where you were on the Earth, you would most likely have a problem with your energy source and electricity. If you were lucky enough to have it, it would probably be too pricy, harmful to the environment, or unstable. As a society, we face a myriad of problems linked to energy and its distribution, e.g. climate change, energy transition, inequality in distribution, blackouts and political abuse. Nowadays, as the whole World is on a verge of an energy crisis, these problems and questions strike even more.

More

The implementation of CTR and what it means for clinical trials in Poland

On January 31, 2022, the Regulation of the European Parliament and the Council of the European Union on clinical trials of medicinal products for human use came into force, repealing Directive 2001/20/EC at the same time.

What the CTR actually is?

The Clinical Trials Regulation is a regulation containing provisions on clinical trials. To better understand the whole problem, it is necessary to consider what they are and what aspects clinical trials contain.

“Clinical trial” means a clinical study – any investigation in relation to humans intended to discover or verify effects of one or more medicinal products, to determine safety and effectiveness of those medicinal products. The former concept of clinical trial needed to be clarified by introducing a broader concept of biomedical research. The issue of the terms introduced in the Regulation will be discussed in more detail at the end of the article.

More

UP